Thematic area:
Smart Implants and Devices
Product:
An implantable device designed for repeated, targeted delivery of cell-based therapies directly into the peritoneal cavity. The device integrates a drug reservoir with a transcutaneous port, enabling safe, controlled infusion and sampling for conditions such as ovarian cancer.
Market:
Targets a substantial oncology segment, particularly ovarian cancer (≈300,000 new global cases per year). Recurrent ovarian cancer patients alone represent a $7–11M/year initial market, with broader applications possible in peritoneal metastases and immunotherapy delivery platforms.
Fit:
Current delivery methods (catheters, injections) are invasive, infection prone, and unsuitable for repeated dosing. This device addresses a high unmet need by enabling safe, repeatable local therapy delivery with strong early preclinical data. Positioned for IP expansion, regulatory planning, and eventual licensing or spinout.
